Vir Biotechnology (VIR) Change in Receivables (2021 - 2024)

Vir Biotechnology has reported Change in Receivables for 4 years, with the latest figure at $8.7 million in Q4 2024.

• Quarterly Change in Receivables rose 142.57% year-over-year to $8.7 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $6.5 million (up 1052.74% YoY) and the FY2024 annual result came in at $6.5 million, up 1052.74% from the prior year.
• Change in Receivables rose to $8.7 million in Q4 2024 per VIR's latest filing, from $54000.0 in the prior quarter.
• Over five years, Change in Receivables peaked at $680.1 million in Q4 2021 and troughed at -$883.8 million in Q2 2022.
• A 4-year average of $778384.6 and a median of $54000.0 in 2024 frame the typical range for Change in Receivables.
• The widest YoY moves for Change in Receivables: up 142.57% in 2024, down 183.65% in 2024.
• Over 4 years, Change in Receivables stood at $680.1 million in 2021, then slumped by 140.9% to -$278.2 million in 2022, then jumped by 101.3% to $3.6 million in 2023, then surged by 142.57% to $8.7 million in 2024.
• According to Business Quant data, Change in Receivables over the past three periods registered $8.7 million, $54000.0, and -$2.7 million for Q4 2024, Q3 2024, and Q2 2024 respectively.